



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

February 2015





# HIV/AIDS Drug Treatment Program

## Monthly Report

© 2015 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.682.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS



This document is best viewed in colour.  
Drug definitions available in the back.



## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

February 2015

N = 6806



Health Authority	Male	Female	All
FRASER	1243	375	1618
INTERIOR	325	97	422
NORTHERN	125	82	207
VANCOUVER COASTAL	3293	444	3737
VANCOUVER ISLAND	610	142	752
	<b>5596</b>	<b>1140</b>	<b>6736</b>
		<b>Unknown/not stated:</b>	<b>70</b>
		<b>Total:</b>	<b>6806</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2010 - February 2015)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2010 - February 2015)








### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (February 2010 - February 2015)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (February 2010 - February 2015)






### 1.6 Percent Distribution of Active Participants by CD4 Count (February 2010 - February 2015)






### 1.7 Percent Distribution of Inactive Participants by CD4 Count (February 2010 - February 2015)






### 1.8 Active and Inactive Participants (February 2010 - February 2015)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (February 2010 - February 2015)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (February 2010 - February 2015)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(February 2010 - February 2015)








1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT  
(February 2010 - February 2015)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(February 2010 - February 2015)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (February 2010 - February 2015)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(February 2010 - February 2015)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (February 2010 - February 2015)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(February 2010 - February 2015)






1.18 Baseline CD4 for Antiretroviral First Starts (February 2010 - February 2015)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART  
(February 2010 - February 2015)**








1.20 Cumulative Resistance Testing Results by Resistance Category  
(February 2010 - February 2015)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (February 2010 - February 2015)





## 2.1 Duration of ARV treatment in the Province of BC, 1987-2015 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	23	5	0	5	5	660	5	<40	4
1988	23	8	0	8	8	475	8	<40	4
1989	22	58	2	60	56	510	59	<40	4
1990	21	63	1	64	59	530	62	<40	4
1991	21	37	3	40	35	630	40	<40	4
1992	21	68	7	75	55	600	75	<40	4
1993	20	147	15	162	146	580	156	<40	4
1994	19	97	12	109	88	550	106	<40	4
1995	18	128	27	155	128	540	149	<40	4
1996	16	383	64	447	378	570	437	<40	4
1997	14	317	39	356	319	600	348	<40	3
1998	14	224	48	272	219	580	254	<40	3
1999	14	186	41	227	191	540	216	<40	3
2000	14	144	38	182	151	580	177	<40	3
2001	13	134	41	175	147	590	173	<40	3
2002	12	141	34	175	147	540	166	<40	3
2003	11	179	34	213	180	605	206	<40	3
2004	10	178	43	221	191	566	210	<40	3
2005	9	208	54	262	220	595	250	<40	4
2006	8	221	46	267	223	540	260	<40	3
2007	8	287	56	343	289	570	330	<40	3
2008	7	324	82	406	349	610	394	<40	3
2009	6	350	78	428	363	610	412	<40	3
2010	5	322	78	400	332	620	381	<40	3
2011	4	384	79	463	392	630	446	<40	3
2012	3	320	69	389	333	620	376	<40	3
2013	2	305	81	386	309	630	371	<40	3
2014	1	342	64	406	363	600	401	<40	4
2015	0	75	11	86	82	505	82	3210	4
<b>Total:</b>		<b>5635</b>	<b>1147</b>	<b>6782</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	6557	785	2429	<40	2151	560
FEB-2014	6570	785	1895	<40	1656	550
MAR-2014	6598	788	2156	<40	1927	550
APR-2014	6611	790	2126	<40	1870	560
MAY-2014	6677	769	2119	<40	1887	560
JUN-2014	6644	784	1994	<40	1766	550
JUL-2014	6682	780	2179	<40	1930	550
AUG-2014	6703	775	2026	<40	1802	570
SEP-2014	6731	770	2284	<40	1997	550
OCT-2014	6763	764	2250	<40	1949	570
NOV-2014	6760	761	1921	<40	1694	580
DEC-2014	6773	766	1895	<40	1664	580
JAN-2015	6749	761	2428	<40	2052	590
FEB-2015	6806	753	1978	<40	1632	580

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	1418	2266	100	6683	76	285
FEB-2014	1439	2213	73	496	67	490
MAR-2014	1441	2179	115	3890	98	340
APR-2014	1451	2159	112	128	90	400
MAY-2014	1422	2331	90	617	76	350
JUN-2014	1475	2074	96	423	82	380
JUL-2014	1467	2119	95	982	76	355
AUG-2014	1459	2183	87	208	72	365
SEP-2014	1458	2194	104	949	90	395
OCT-2014	1444	2300	84	257	62	395
NOV-2014	1458	2249	73	3208	63	410
DEC-2014	1478	2221	93	557	68	340
JAN-2015	1515	2090	105	1364	80	290
FEB-2015	1491	2199	99	78	78	385

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2014	6539	1418	2	30	144	136	35	11501
FEB-2014	6548	1439	9	40	139	159	9	11545
MAR-2014	6573	1441	9	36	151	146	25	11589
APR-2014	6587	1451	5	27	159	161	14	11625
MAY-2014	6646	1422	14	38	191	152	59	11675
JUN-2014	6618	1475	7	24	142	183	-28	11713
JUL-2014	6659	1467	8	34	176	159	41	11757
AUG-2014	6683	1459	6	18	165	149	24	11789
SEP-2014	6714	1458	2	25	168	158	31	11828
OCT-2014	6741	1444	7	21	160	145	27	11855
NOV-2014	6735	1458	11	19	135	145	-6	11879
DEC-2014	6749	1478	8	39	136	148	14	11928
JAN-2015	6720	1515	12	23	148	183	-29	11963
FEB-2015	6782	1491	5	37	188	157	62	12015

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





**2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs**

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2014	47	6025	414	71	<b>6557</b>	0.72%	91.89%	6.31%	1.08%	<b>100.00%</b>
FEB-2014	50	6034	418	68	<b>6570</b>	0.76%	91.84%	6.36%	1.04%	<b>100.00%</b>
MAR-2014	50	6054	424	70	<b>6598</b>	0.76%	91.76%	6.43%	1.06%	<b>100.00%</b>
APR-2014	46	6067	422	76	<b>6611</b>	0.70%	91.77%	6.38%	1.15%	<b>100.00%</b>
MAY-2014	47	6138	418	74	<b>6677</b>	0.70%	91.93%	6.26%	1.11%	<b>100.00%</b>
JUN-2014	49	6108	416	71	<b>6644</b>	0.74%	91.93%	6.26%	1.07%	<b>100.00%</b>
JUL-2014	46	6148	415	73	<b>6682</b>	0.69%	92.01%	6.21%	1.09%	<b>100.00%</b>
AUG-2014	46	6171	414	72	<b>6703</b>	0.69%	92.06%	6.18%	1.07%	<b>100.00%</b>
SEP-2014	49	6185	426	71	<b>6731</b>	0.73%	91.89%	6.33%	1.05%	<b>100.00%</b>
OCT-2014	44	6211	435	73	<b>6763</b>	0.65%	91.84%	6.43%	1.08%	<b>100.00%</b>
NOV-2014	47	6219	424	70	<b>6760</b>	0.70%	92.00%	6.27%	1.04%	<b>100.00%</b>
DEC-2014	43	6235	421	74	<b>6773</b>	0.63%	92.06%	6.22%	1.09%	<b>100.00%</b>
JAN-2015	43	6192	440	74	<b>6749</b>	0.64%	91.75%	6.52%	1.10%	<b>100.00%</b>
FEB-2015	42	6239	452	73	<b>6806</b>	0.62%	91.67%	6.64%	1.07%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	8 19%	2382 37%	7 17%	1995 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3864 61%	36 86%	4271 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3881 61%	37 84%	4287 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3904 61%	33 92%	4301 67%
MAY-2014	17 34%	2434 38%	16 32%	2058 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3929 61%	33 66%	4325 67%
JUN-2014	8 21%	2431 38%	9 24%	2063 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	29 76%	3905 61%	29 76%	4293 67%
JUL-2014	13 30%	2462 38%	11 25%	2095 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3918 60%	32 73%	4298 66%
AUG-2014	7 23%	2474 38%	7 23%	2108 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3913 60%	24 77%	4287 66%
SEP-2014	15 38%	2517 39%	12 31%	2146 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3907 60%	24 62%	4287 66%
OCT-2014	10 37%	2546 39%	9 33%	2173 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 63%	3909 60%	17 63%	4290 65%
NOV-2014	6 25%	2548 39%	6 25%	2183 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3898 59%	19 79%	4271 65%
DEC-2014	13 27%	2576 39%	9 18%	2205 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3878 59%	37 76%	4250 65%
JAN-2015	10 29%	2585 39%	10 29%	2222 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3856 59%	25 71%	4220 64%
FEB-2015	10 19%	2596 39%	10 19%	2231 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	42 81%	3898 59%	42 81%	4260 65%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS







**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	740 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	762 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2259 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2249 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	3 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	5 31%	2198 63%	9 56%	831 24%	2 13%	449 13%	0 0%	5 0%	0 0%	3 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2182 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2153 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2140 62%	6 46%	868 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2135 62%	5 50%	889 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2108 62%	2 17%	893 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
DEC-2014	0 0%	13 0%	7 32%	2076 61%	12 55%	922 27%	3 14%	386 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
JAN-2015	0 0%	12 0%	6 50%	2032 60%	6 50%	933 28%	0 0%	384 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	9 33%	2036 60%	18 67%	960 28%	0 0%	381 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%
DEC-2014	0	0%	1	0%
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	5 71%	1298 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	4 50%	1280 46%	1 13%	303 11%	1 13%	926 34%	2 25%	258 9%
JUL-2014	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	257 9%
AUG-2014	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	3 60%	1232 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	2 100%	1208 45%	0 0%	302 11%	0 0%	911 34%	0 0%	252 9%
DEC-2014	8 62%	1191 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	901 34%	2 25%	254 10%
FEB-2015	4 50%	1170 45%	0 0%	305 12%	0 0%	893 34%	4 50%	251 10%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	77 6%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	253 17%	0 0%	75 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	268 18%	0 0%	75 5%	2 18%	919 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	282 18%	0 0%	74 5%	4 27%	919 58%	0 0%	1 0%
OCT-2014	7 47%	406 25%	6 40%	310 19%	0 0%	71 4%	2 13%	906 55%	0 0%	1 0%
NOV-2014	5 45%	452 27%	5 45%	325 19%	0 0%	70 4%	1 9%	893 53%	0 0%	1 0%
DEC-2014	11 65%	500 29%	6 35%	336 19%	0 0%	72 4%	0 0%	888 51%	0 0%	1 0%
JAN-2015	13 72%	542 30%	4 22%	350 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 61%	578 31%	7 30%	360 19%	0 0%	74 4%	2 9%	881 48%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2542	38.45	2288	34.61	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2537	38.00	2275	34.07	739	11.07	193	2.89	74	1.11	859	12.87
JUN-2014	2502	37.66	2246	33.80	782	11.77	183	2.75	71	1.07	860	12.94
JUL-2014	2493	37.31	2235	33.45	840	12.57	191	2.86	73	1.09	850	12.72
AUG-2014	2465	36.77	2232	33.30	890	13.28	186	2.77	72	1.07	858	12.80
SEP-2014	2438	36.22	2221	33.00	945	14.04	187	2.78	71	1.05	869	12.91
OCT-2014	2421	35.80	2191	32.40	1008	14.90	192	2.84	73	1.08	878	12.98
NOV-2014	2423	35.84	2160	31.95	1056	15.62	184	2.72	70	1.04	867	12.83
DEC-2014	2401	35.45	2146	31.68	1104	16.30	185	2.73	74	1.09	863	12.74
JAN-2015	2355	34.89	2125	31.49	1139	16.88	179	2.65	74	1.10	877	12.99
FEB-2015	2375	34.90	2114	31.06	1181	17.35	177	2.60	73	1.07	886	13.02

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	24	3	1	6	6	7	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	21	1	4	6	4	5	315
NOV-2014	19	5	1	0	4	8	475
DEC-2014	39	3	5	7	11	13	401
JAN-2015	23	2	2	8	3	8	320
FEB-2015	37	3	3	8	5	16	457

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2014	10030	2581
FEB-2014	10054	2575
MAR-2014	10067	2561
APR-2014	10097	2564
MAY-2014	10121	2558
JUN-2014	10156	2568
JUL-2014	10168	2556
AUG-2014	10217	2590
SEP-2014	10259	2600
OCT-2014	10282	2609
NOV-2014	10314	2631
DEC-2014	10354	2635
JAN-2015	10398	2665
FEB-2015	10446	2672

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved  
**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
February 2015

N = 6806

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY









3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2015

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2015

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2015

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2015

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2015

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	11	13	8
	50+	19	29	13
	<b>Total HSDA:</b>	<b>30</b>	<b>42</b>	<b>21</b>
KOOTENAY BOUNDARY	0-19	1	1	1
	20-34	4	4	2
	35-49	19	24	12
	50+	43	57	34
	<b>Total HSDA:</b>	<b>67</b>	<b>86</b>	<b>49</b>
OKANAGAN	0-19	3	3	2
	20-34	20	21	16
	35-49	95	111	69
	50+	173	254	134
	<b>Total HSDA:</b>	<b>291</b>	<b>389</b>	<b>221</b>
THOMPSON/CARIBOO/ SHUSWAP	0-19	6	6	1
	20-34	16	16	12
	35-49	55	71	42
	50+	87	123	76
	<b>Total HSDA:</b>	<b>164</b>	<b>216</b>	<b>131</b>
<b>Total HA:</b>		<b>552</b>	<b>733</b>	<b>422</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	4
	20-34	40	41	30
	35-49	180	219	131
	50+	322	463	257
<b>Total HA:</b>		<b>552</b>	<b>733</b>	<b>422</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	424	576	325
Female	128	157	97

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	422	52	530	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration  
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	6	4
	<5 years	8	7
	<b>Total HSDA:</b>	<b>30</b>	<b>21</b>
KOOTENAY BOUNDARY	10 years or more	32	22
	5 years or more	16	13
	<5 years	19	14
	<b>Total HSDA:</b>	<b>67</b>	<b>49</b>
OKANAGAN	10 years or more	152	106
	5 years or more	72	57
	<5 years	67	58
	<b>Total HSDA:</b>	<b>291</b>	<b>221</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	83	60
	5 years or more	33	30
	<5 years	48	41
	<b>Total HSDA:</b>	<b>164</b>	<b>131</b>
<b>Total HA:</b>		<b>552</b>	<b>422</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	283	198
	5 years or more	127	104
	<5 years	142	120
<b>Total HA:</b>		<b>552</b>	<b>422</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	33	45	12	18
KOOTENAY BOUNDARY	58	105	26	40
OKANAGAN	185	625	69	221
THOMPSON/CARIBOO/SHUSWAP	121	398	44	103
<b>Total:</b>	<b>397</b>	<b>1173</b>	<b>151</b>	<b>382</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	2
KOOTENAY BOUNDARY	12
OKANAGAN	40
THOMPSON/CARIBOO/SHUSWAP	35
<b>Total:</b>	<b>89</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA







#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	22	23	17
	35-49	126	139	90
	50+	143	200	111
	<b>Total HSDA:</b>	<b>298</b>	<b>369</b>	<b>223</b>
FRASER NORTH	0-19	22	22	5
	20-34	101	102	88
	35-49	364	416	273
	50+	423	663	347
	<b>Total HSDA:</b>	<b>910</b>	<b>1203</b>	<b>713</b>
FRASER SOUTH	0-19	14	14	7
	20-34	88	89	70
	35-49	361	410	294
	50+	368	555	311
	Unknown	0	1	0
	<b>Total HSDA:</b>	<b>831</b>	<b>1069</b>	<b>682</b>
<b>Total HA:</b>		<b>2039</b>	<b>2641</b>	<b>1618</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	43	43	17
	20-34	211	214	175
	35-49	851	965	657
	50+	934	1418	769
	Unknown	0	1	0
<b>Total HA:</b>		<b>2039</b>	<b>2641</b>	<b>1618</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1537	2024	1243
Female	502	617	375

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1618	49	590	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	133	94
	5 years or more	92	71
	<5 years	73	58
	<b>Total HSDA:</b>	<b>298</b>	<b>223</b>
FRASER NORTH	10 years or more	429	308
	5 years or more	228	180
	<5 years	253	225
	<b>Total HSDA:</b>	<b>910</b>	<b>713</b>
FRASER SOUTH	10 years or more	377	294
	5 years or more	215	181
	<5 years	239	207
	<b>Total HSDA:</b>	<b>831</b>	<b>682</b>
<b>Total HA:</b>		<b>2039</b>	<b>1618</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	939	696
	5 years or more	535	432
	<5 years	565	490
<b>Total HA:</b>		<b>2039</b>	<b>1618</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	121	361	40	75
FRASER NORTH	224	1313	66	256
FRASER SOUTH	196	1128	47	349
<b>Total:</b>	<b>541</b>	<b>2802</b>	<b>153</b>	<b>680</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	174
FRASER NORTH	601
FRASER SOUTH	463
<b>Total:</b>	<b>1238</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	3	3	1
	20-34	18	18	16
	35-49	84	98	69
	50+	190	308	164
	<b>Total HSDA:</b>	<b>295</b>	<b>427</b>	<b>250</b>
RICHMOND	0-19	8	8	2
	20-34	17	17	15
	35-49	50	53	41
	50+	66	105	55
	<b>Total HSDA:</b>	<b>141</b>	<b>183</b>	<b>113</b>
VANCOUVER	0-19	59	62	9
	20-34	397	406	301
	35-49	1661	1964	1278
	50+	2241	3729	1786
	<b>Total HSDA:</b>	<b>4358</b>	<b>6161</b>	<b>3374</b>
<b>Total HA:</b>		<b>4794</b>	<b>6771</b>	<b>3737</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	70	73	12
	20-34	432	441	332
	35-49	1795	2115	1388
	50+	2497	4142	2005
<b>Total HA:</b>		<b>4794</b>	<b>6771</b>	<b>3737</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4206	5947	3293
Female	586	822	444

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3737	50	600	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	166	136
	5 years or more	45	41
	<5 years	84	73
	<b>Total HSDA:</b>	<b>295</b>	<b>250</b>
RICHMOND	10 years or more	67	49
	5 years or more	31	23
	<5 years	43	41
	<b>Total HSDA:</b>	<b>141</b>	<b>113</b>
VANCOUVER	10 years or more	2146	1547
	5 years or more	1042	844
	<5 years	1170	983
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4358</b>	<b>3374</b>
<b>Total HA:</b>	<b>4794</b>	<b>3737</b>	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2379	1732
5 years or more	1118	908
<5 years	1297	1097
Never on ART	0	0
<b>Total HA:</b>	<b>4794</b>	<b>3737</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	137	354	54	88
RICHMOND	41	262	15	96
VANCOUVER	510	9479	206	5150
<b>Total:</b>	<b>688</b>	<b>10095</b>	<b>275</b>	<b>5334</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	5
RICHMOND	3
VANCOUVER	91
<b>Total:</b>	<b>99</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	17	19	14
	35-49	80	95	70
	50+	146	236	116
	<b>Total HSDA:</b>		<b>245</b>	<b>352</b>
NORTH VANCOUVER ISLAND	0-19	2	2	1
	20-34	11	12	7
	35-49	37	42	32
	50+	54	81	45
	<b>Total HSDA:</b>		<b>104</b>	<b>137</b>
SOUTH VANCOUVER ISLAND	0-19	9	9	1
	20-34	43	45	28
	35-49	213	254	161
	50+	358	558	276
	<b>Total HSDA:</b>		<b>623</b>	<b>866</b>
<b>Total HA:</b>		<b>972</b>	<b>1355</b>	<b>752</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	3
	20-34	71	76	49
	35-49	330	391	263
	50+	558	875	437
<b>Total HA:</b>		<b>972</b>	<b>1355</b>	<b>752</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	783	1096	610
Female	189	259	142

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	752	51	460	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	110	85
	5 years or more	67	56
	<5 years	68	60
	<b>Total HSDA:</b>	<b>245</b>	<b>201</b>
NORTH VANCOUVER ISLAND	10 years or more	47	36
	5 years or more	21	19
	<5 years	36	30
	<b>Total HSDA:</b>	<b>104</b>	<b>85</b>
SOUTH VANCOUVER ISLAND	10 years or more	306	215
	5 years or more	153	116
	<5 years	164	135
	<b>Total HSDA:</b>	<b>623</b>	<b>466</b>
<b>Total HA:</b>		<b>972</b>	<b>752</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	463	336
	5 years or more	241	191
	<5 years	268	225
<b>Total HA:</b>		<b>972</b>	<b>752</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation







**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	165	505	85	162
NORTH VANCOUVER ISLAND	108	224	47	66
SOUTH VANCOUVER ISLAND	177	1464	47	503
<b>Total:</b>	<b>450</b>	<b>2193</b>	<b>179</b>	<b>731</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	46
NORTH VANCOUVER ISLAND	30
SOUTH VANCOUVER ISLAND	82
<b>Total:</b>	<b>158</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	5	6	4
	35-49	17	20	7
	50+	14	18	10
	<b>Total HSDA:</b>		<b>37</b>	<b>45</b>
NORTH WEST	0-19	2	2	0
	20-34	9	13	7
	35-49	23	34	19
	50+	30	43	23
	<b>Total HSDA:</b>		<b>64</b>	<b>92</b>
NORTHERN INTERIOR	0-19	1	1	0
	20-34	29	32	24
	35-49	71	86	58
	50+	70	114	55
	<b>Total HSDA:</b>		<b>171</b>	<b>233</b>
<b>Total HA:</b>		<b>272</b>	<b>370</b>	<b>207</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	4	4	0
	20-34	43	51	35
	35-49	111	140	84
	50+	114	175	88
<b>Total HA:</b>		<b>272</b>	<b>370</b>	<b>207</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	168	233	125
Female	104	137	82

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	207	46	490	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	12	7
	5 years or more	9	4
	<5 years	16	10
	<b>Total HSDA:</b>	<b>37</b>	<b>21</b>
NORTH WEST	10 years or more	17	8
	5 years or more	22	19
	<5 years	25	22
	<b>Total HSDA:</b>	<b>64</b>	<b>49</b>
NORTHERN INTERIOR	10 years or more	45	28
	5 years or more	46	41
	<5 years	80	68
	<b>Total HSDA:</b>	<b>171</b>	<b>137</b>
<b>Total HA:</b>		<b>272</b>	<b>207</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	74	43
	5 years or more	77	64
	<5 years	121	100
<b>Total HA:</b>		<b>272</b>	<b>207</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	27	54	4	6
NORTH WEST	58	135	19	26
NORTHERN INTERIOR	94	362	24	178
<b>Total:</b>	<b>179</b>	<b>551</b>	<b>47</b>	<b>210</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	8
NORTH WEST	20
NORTHERN INTERIOR	27
<b>Total:</b>	<b>55</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender**

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	9	6
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	15	28	8
	THOMPSON/CARIBOO/SHUSWAP	20	35	20
	<b>Total HA:</b>	<b>44</b>	<b>78</b>	<b>37</b>
FRASER	FRASER EAST	33	41	28
	FRASER NORTH	66	94	46
	FRASER SOUTH	70	96	52
	<b>Total HA:</b>	<b>169</b>	<b>231</b>	<b>126</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	22	41	19
	RICHMOND	9	14	8
	VANCOUVER	476	745	407
	<b>Total HA:</b>	<b>507</b>	<b>800</b>	<b>434</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	44	69	37
	NORTH VANCOUVER ISLAND	12	21	12
	SOUTH VANCOUVER ISLAND	32	66	24
	<b>Total HA:</b>	<b>88</b>	<b>156</b>	<b>73</b>
NORTHERN	NORTH EAST	8	10	6
	NORTH WEST	28	49	23
	NORTHERN INTERIOR	63	91	59
	<b>Total HA:</b>	<b>99</b>	<b>150</b>	<b>88</b>
<b>Total:</b>		<b>907</b>	<b>1415</b>	<b>758</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	576	912	467
Female	331	503	291

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	758	48	460	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** Persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Boosted PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Combination Therapy:** using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

**Complera (CPL):** the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Delavirdine (Rescriptor, DLV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.





**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

**Efavirenz (Sustiva, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

**Emtricitabine (FTC):** a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**Famciclovir (Famvir):** a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

**Indinavir (Crixivan, IDV):** a PROTEASE INHIBITOR from Merck.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.





**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

**Maraviroc (MVC, Celsentri):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** The net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).







**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

**Tenofovir (Viread, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Trizivir (TRZ):** ViiV Healthcare's trade name for a pill that combines ABACAVIR (ABC), ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

**Truvada (TRU):** the Gilead trade name for a pill that contains both TENOFOVIR and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

